GR3007202T3 - - Google Patents

Info

Publication number
GR3007202T3
GR3007202T3 GR930400447T GR930400447T GR3007202T3 GR 3007202 T3 GR3007202 T3 GR 3007202T3 GR 930400447 T GR930400447 T GR 930400447T GR 930400447 T GR930400447 T GR 930400447T GR 3007202 T3 GR3007202 T3 GR 3007202T3
Authority
GR
Greece
Prior art keywords
azelastine
administration
medicine
active ingredient
physiologically tolerated
Prior art date
Application number
GR930400447T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6340483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3007202(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3007202T3 publication Critical patent/GR3007202T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
GR930400447T 1987-11-13 1993-03-02 GR3007202T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3738681 1987-11-13

Publications (1)

Publication Number Publication Date
GR3007202T3 true GR3007202T3 (el) 1993-07-30

Family

ID=6340483

Family Applications (1)

Application Number Title Priority Date Filing Date
GR930400447T GR3007202T3 (el) 1987-11-13 1993-03-02

Country Status (15)

Country Link
US (1) US5164194A (el)
EP (1) EP0316633B1 (el)
JP (3) JP2911460B2 (el)
AT (1) ATE84968T1 (el)
AU (1) AU613107B2 (el)
CA (1) CA1319322C (el)
DE (1) DE3877904D1 (el)
DK (1) DK174928B1 (el)
ES (1) ES2053678T3 (el)
GR (1) GR3007202T3 (el)
IE (1) IE61562B1 (el)
NL (1) NL990011I1 (el)
PT (1) PT88985B (el)
YU (1) YU46988B (el)
ZA (1) ZA888461B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68347T1 (de) * 1987-01-17 1991-11-15 Asta Pharma Ag Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
JP2005281315A (ja) * 1997-07-02 2005-10-13 Aventis Pharmaceuticals Holdings Inc 水性薬理組成物
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
KR20020050275A (ko) * 1999-11-11 2002-06-26 다케다 야쿠힌 고교 가부시키가이샤 융합 피리다진 유도체를 함유하는 점비제
WO2001052818A1 (en) * 2000-01-19 2001-07-26 Pharmaceutical Discovery Corporation Dry powder formulations of antihistamine for nasal administration
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt Immun Gmbh Nasensalbe auf Basis von Vaselin
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
WO2002056876A2 (en) * 2001-01-18 2002-07-25 Medpointe Healthcare Inc. Treatment for snoring
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US6641799B2 (en) 2002-04-03 2003-11-04 Nos Spray, Inc. Nasal spray for decongesting nasal passages
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
DE60333205D1 (de) * 2002-08-30 2010-08-12 Nycomed Gmbh Histaminika zur behandlung von allergischer rhinitis
JP2007501252A (ja) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
WO2005074983A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
GB2423711B (en) 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
US7378082B1 (en) * 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
AU2008343045A1 (en) * 2007-12-21 2009-07-09 Msd Consumer Care, Inc. Enhancing photostabilization of oxymetazoline
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
KR101261230B1 (ko) 2010-11-29 2013-05-07 한림제약(주) 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
KR102192384B1 (ko) * 2018-12-17 2020-12-17 최연서 광원이 회전 가능한 cob형 led 조명 장치
CA3181959A1 (en) 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
AU2021437358A1 (en) 2021-04-01 2023-09-14 Alkem Laboratories Limited Nasal compositions comprising alcaftadine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158564A (en) * 1875-01-12 Improvement in medicine-droppers
US2119643A (en) * 1934-11-07 1938-06-07 Mendl Viktor Pressure-operated diffuser of toilet-liquids
US2136940A (en) * 1936-07-02 1938-11-15 Aromel Corp Atomizer
US2457024A (en) * 1945-02-13 1948-12-21 Arp Claus Collapsible tube holder
US2995308A (en) * 1958-09-23 1961-08-08 American Home Prod Jet stream dispenser
CH572914A5 (el) * 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
DE3530793A1 (de) * 1984-09-14 1986-03-27 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld Substituierte benzylphthalazinon-derivate
EP0174464B1 (de) * 1984-09-14 1990-01-03 ASTA Pharma AG Substituierte Benzylphthalazinon-Derivate
US4769369A (en) * 1986-11-14 1988-09-06 Pennwalt Corporation Anti-allergy 1(2H)-phthalazinones

Also Published As

Publication number Publication date
US5164194A (en) 1992-11-17
JP2911460B2 (ja) 1999-06-23
AU2506388A (en) 1989-05-18
JPH01153639A (ja) 1989-06-15
AU613107B2 (en) 1991-07-25
CA1319322C (en) 1993-06-22
NL990011I1 (nl) 1999-07-01
ATE84968T1 (de) 1993-02-15
JP3207816B2 (ja) 2001-09-10
EP0316633B1 (de) 1993-01-27
IE883403L (en) 1989-05-13
ZA888461B (en) 1989-08-30
JPH11349484A (ja) 1999-12-21
ES2053678T3 (es) 1994-08-01
JP2956029B2 (ja) 1999-10-04
YU46988B (sh) 1994-09-09
PT88985A (pt) 1988-12-01
EP0316633A1 (de) 1989-05-24
DK174928B1 (da) 2004-03-01
DK630188A (da) 1989-05-14
YU209288A (en) 1990-04-30
DE3877904D1 (de) 1993-03-11
PT88985B (pt) 1993-01-29
DK630188D0 (da) 1988-11-11
JPH10182464A (ja) 1998-07-07
IE61562B1 (en) 1994-11-16

Similar Documents

Publication Publication Date Title
GR3007202T3 (el)
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
ES2077530A1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
ZA894728B (en) A new pharmaceutical formulation as well as a process for its preparation
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
PT86186A (en) Process for the preparation of benzimidazol derivatives and of pharmaceutical compositions containing the same
IE882391L (en) Pad printing process
ES2179832T3 (es) Formas de administracion orales con contenido en flupirtina solida, con liberacion controlada del principio activo.
ES2060685T3 (es) Medicamento con contenido de azelastina con liberacion controlada del principio activo.
GR890100833A (en) Process for the preparation of a compound with gastric inhibitopy effect
EP0484112A3 (en) Use of lithium in the treatment or prophylaxis of molluscum contagiosum
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
ES2057008T3 (es) Medicamento.
GR3018365T3 (en) Use of 15-deoxyspergualine as a medicament.
PT97052A (pt) Processo para a preparacao de composicoes farmaceuticas contendo bambuterol, apropriadas para diminuir o teor de lipidos no sangue
EP0316639A3 (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
DE3879837T2 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
IT1243368B (it) Uso del bendazac e dei suoi sali farmaceuticamente accettabili